Mobiliser l'immunité innée dans le traitement des cancers

Immunotherapies are particularly attractive when one wants to fight cancer since they aim at controlling the immune system in order to eradicate cancer cells and prevent tumor dissemination. While the clinical use of specific ligands for the innate immune receptors is promising, it is still facing several drawbacks when entering clinical trials. Nevertheless, recent advances in our understanding of the biology of these receptors constrain us to re-assess existing strategies and let foresee new approaches in the pipeline of therapies that would overcome current limitations.